Krystal Biotech (KRYS) Change in Acquisitions & Divestments (2019 - 2026)

Krystal Biotech has reported Change in Acquisitions & Divestments for 8 years, with the latest figure at $100.0 million in Q2 2026.

• Change in Acquisitions & Divestments for Q2 2026 came in at $100.0 million, down 5.01% year-over-year; the trailing twelve-month figure through Jun 2026 was $385.2 million (up 15.38% YoY), and the FY2025 annual result was $375.6 million, up 25.83% from the prior year.
• Change in Acquisitions & Divestments fell to $100.0 million in Q2 2026, from $103.6 million in the prior quarter.
• Over five years, Change in Acquisitions & Divestments peaked at $161.2 million in Q2 2023 and troughed at $24.0 million in Q1 2022.
• A 5-year average of $91.0 million and a median of $92.0 million in 2024 frame the typical range for Change in Acquisitions & Divestments.
• The widest annual swing landed in 2022, when Change in Acquisitions & Divestments jumped 4992.62%; it then tumbled 58.83% in 2024.
• A 5-year view of Change in Acquisitions & Divestments shows it stood at $104.1 million in 2022, then slipped by 28.33% to $74.6 million in 2023, then declined by 18.9% to $60.5 million in 2024, then jumped by 41.77% to $85.8 million in 2025, then increased by 16.6% to $100.0 million in 2026.
• Per Business Quant data, the three most recent Change in Acquisitions & Divestments figures were $100.0 million in Q2 2026, $103.6 million in Q1 2026, and $85.8 million in Q4 2025.